The mitotic checkpoint is a targetable vulnerability of carboplatin-resistant triple negative breast cancers

The mitotic checkpoint is a targetable vulnerability of carboplatin-resistant triple negative breast cancers

Abstract Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype, lacking effective therapy. Many TNBCs show remarkable response to carboplatin-based chemotherapy, but often develop resistance over time. With increasing use of carboplatin in the clinic, there is a pressing...

Full description

Bibliographic Details
Main Authors: Stijn Moens, Peihua Zhao, Maria Francesca Baietti, Oliviero Marinelli, Delphi Van Haver, Francis Impens, Giuseppe Floris, Elisabetta Marangoni, Patrick Neven, Daniela Annibali, Anna A. Sablina, Frédéric Amant
Format: Article
Language:English
Published: Nature Publishing Group 2021-02-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-82780-6

Internet

https://doi.org/10.1038/s41598-021-82780-6

Similar Items